The Global Thin Film Drugs Market is estimated to grow at a CAGR of 9.1% during the forecast period. Thin films are a modern addition to the world of pharmaceutical dosage forms. These can be used to give medications via oral, buccal, sublingual, transdermal, vaginal, and rectal routes, among others. These are intended for rapid disintegration and release of the medicine in the oral cavity for quick therapeutic effect, without the usage of water for swallowing, when given via oral route. These are becoming increasingly popular among patients of all ages, particularly among the pediatric and geriatric patients. Passive diffusion, endocytosis, and carrier-mediated transport are all the methods of drug absorption into the systemic circulation. The oral route helps to enhance bioavailability by avoiding hepatic first pass metabolism. Because this formulation has a modest drug load (less than 50 mg), it helps to reduce undesired side effects.

Furthermore, pharmaceutical companies are increasing their efforts in research and development initiatives, which is driving the market growth. Patients may benefit from oral thin film medications, since they are easy to store and transport. Furthermore, these provide exact and accurate dosing, resulting in the desired beneficial result. As a result, the thin film drug delivery system market has gained a lot of traction.  The global oral thin film market has been driven even further, by a high level of acceptability and remarkable benefits.

Comprehensive competitive analysis and profiles of major market players such as MonoSol Rx, TesaLabtec GmbH, Pfizer, Inc., Novartis AG, Wolters Kluwer, Solvay, Allergan plc., Sumitomo Dainippon Pharma Co., Ltd., IntelGenx Corp, and Transition Therapeutics, Inc.  to maintain a strong position in the market, with adopting various strategies such as product launches, partnerships, collaborations, and mergers and acquisitions.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segments Covered

o By Product 

o By Disease Indication

o By Distribution Channel

    • Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

    • Competitive Landscape: MonoSol Rx, TesaLabtec GmbH, Pfizer, Inc., Novartis AG, Wolters Kluwer among others.

Key questions addressed by the report: 

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Thin Film Drugs Market by Segmentation

By Product

    • Fast Dissolving Buccal Film

    • Sublingual

By Disease Indication

    • Nausea and Vomiting

    • Opioid Dependence

    • Schizophrenia

    • Migraine

    • Others

By Distribution Channel

    • Retail Pharmacies

    • Hospital Pharmacies

    • Online Drug Stores

    • Others

Global Thin Film Drugs Market by Region

North America       

    • United States 

    • Canada

Europe

    • Germany

    • United Kingdom

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa